Table 1. Characteristics of all studies included in the meta-analysis for quantitative synthesis.
| Study | Resectability | Region | Multi- or single-centre | FOLFIRINOX-treated patients | GA-treated patients | Decision for neoadjuvant | NOS score |
|---|---|---|---|---|---|---|---|
| Dhir et al., 2018 | RPC and BRPC | United States | Single-centre | 73 | 120 | Multidisciplinary tumour board | 7 |
| Chapman et al., 2018 | BRPC and LAPC | United States | Single-centre | 55 | 12 | Pancreatic and biliary multidisciplinary team | 7 |
| Perri et al., 2020 | RPC, BRPC and LAPC | United States | Single-centre | 140 | 140 | NA | 8 |
| Wolfe et al., 2020 | BRPC or LAPC | United States | Single-centre | 52 | 20 | Multidisciplinary pancreatic oncology team | 6 |
| Macedo et al., 2019 | RPC, BRPC and LAPC | United States | Multi-centre | 183 | 91 | Medical or radiation oncologists | 7 |
| Napolitano et al., 2019 | LAPC | Europe (Italy) | Single-centre | 35 | 21 | Multidisciplinary teamwork | 6 |
| Weniger et al., 2020 | LAPC and BRPC | Europe (Germany) | Multi-centre | 103 | 32 | Multi-disciplinary decision | 6 |
| Gage et al., 2019 | NA* | United States | Single-centre | 105 | 175 | NA | 5 |
*, the authors declared in the “Methods” section that the patients they enrolled underwent neoadjuvant chemotherapy followed by Whipple procedures (the proportions of each type were not presented). GA, gemcitabine and nab-paclitaxel; RPC, resectable pancreatic cancer; BRPC, borderline resectable pancreatic cancer; LAPC, locally advanced pancreatic cancer; NOS, Newcastle-Ottawa Scale.